Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. (NASDAQ: RXST) is an ophthalmic medical device company whose news flow centers on its Light Adjustable Lens system and corporate developments related to cataract surgery care. Company press releases describe RxSight as dedicated to providing high-quality customized vision to patients following cataract surgery through its Light Adjustable Lens (LAL/LAL+) and Light Delivery Device (LDD) platform.
News updates for RXST commonly include financial and operating results, such as quarterly revenue, procedure volumes for Light Adjustable Lenses, and the number of Light Delivery Devices sold and installed. These releases often discuss trends in LAL procedure volumes, changes in the installed base of LDDs, and guidance ranges for revenue and gross margin. Investors and observers can use these announcements to track how adoption of the Light Adjustable Lens system is progressing across cataract practices.
RxSight’s news also highlights corporate and leadership developments, including transitions in the Chief Financial Officer role and appointments to the Board of Directors and Board committees, as disclosed in press releases and related Form 8-K filings. In addition, the company regularly announces participation in major healthcare and ophthalmology conferences, where management presents to investors and engages with surgeons and other stakeholders.
Another recurring theme in RxSight’s news is commercial and clinical engagement activity. The company has reported initiatives such as practice development programs and Live Learning Sessions at ophthalmology meetings, where surgeons share real-world experience with the Light Adjustable Lens and discuss clinical and practice-level impacts.
This RXST news page aggregates these types of updates in one place, allowing readers to follow RxSight’s reported financial performance, leadership changes, conference participation, and initiatives related to its Light Adjustable Lens technology over time.
RxSight, Inc. reported significant financial growth for Q2 2022, with revenues of $11.4 million, marking a 132% increase year-over-year. The company's sales included 49 Light Delivery Devices (LDDs), a 96% increase, and 5,400 Light Adjustable Lenses (LALs), representing a 196% rise in procedures. Full-year revenue guidance is now set at $44.0 to $46.0 million, indicating a growth rate of 95% to 104% compared to 2021. Despite a net loss of $(16.7) million, the company is seeing robust demand for its products.
RxSight, Inc. (NASDAQ: RXST) will report its Q2 2022 financial results on August 8, 2022, after market close. A conference call is scheduled for 1:30 PM PT / 4:30 PM ET to discuss these results. Interested parties can access a live and archived webcast via the Investors page on RxSight's website. The company is focused on improving post-cataract surgery vision with its unique RxSight Light Adjustable Lens system, which includes advanced ActivShield technology. More details are available on their website.
RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q1 2022, achieving $8.9 million in revenue, a 157% increase from Q1 2021. Key drivers included a sale of 40 Light Delivery Devices (LDDs) and 4,166 Light Adjustable Lenses (LALs), marking growth of 208% and 166% in volume, respectively. Gross profit also surged to $3.7 million (42% of revenue). However, operating expenses rose 66% to $20.3 million, resulting in a net loss of $17.6 million. The company has revised its 2022 revenue guidance upward to $41.5 million to $45.5 million.
RxSight, a medical device company focused on ophthalmic solutions, will present at the Bank of America Healthcare Conference on May 10, 2022, at 12:00 PM PT. This event will showcase the company's innovative RxSight Light Adjustable Lens system, which allows for customized visual acuity post-cataract surgery. The system now includes ActivShield technology for added UV protection. A live and archived webcast of the presentation will be available on their website under the 'Investors' section.
RxSight, Inc. (NASDAQ: RXST) will announce its Q1 2022 financial results on May 5, 2022, after market close. A conference call to discuss the results is scheduled for 1:30 PM PT / 4:30 PM ET the same day. Investors can access the call via the company's website or by phone. The company specializes in ophthalmic medical devices, particularly the Light Adjustable Lens (LAL), a unique intraocular lens technology that enhances post-cataract surgery vision. The LAL includes the new ActivShield™ technology for UV protection.
RxSight, Inc. (NASDAQ: RXST) announced that its Light Adjustable Lens (LAL) system will be featured in multiple presentations at the annual ASCRS meeting in Washington D.C. from April 22-26, 2022. Key presentations include studies on clinical outcomes, patient satisfaction, and visual acuities relative to LAL. The company highlights the revolutionary features of the LAL, including its ability to be optimized post-implantation, and the new ActivShield technology for UV protection. RxSight aims to enhance patient vision after cataract surgery and expand the revenue potential for medical practitioners.
RxSight, Inc. (NASDAQ: RXST), a medical device company focused on enhancing vision after cataract surgery, announced participation in the Needham Virtual Healthcare Conference. Management will present on April 11, 2022, at 12:45 PM PT / 3:45 PM ET. The presentation can be accessed live and archived via the company’s website. RxSight is known for its Light Adjustable Lens (LAL) system, the first IOL technology allowing doctors to customize visual acuity post-surgery, which now includes ActivShield™ technology for UV protection.
RxSight, Inc. (NASDAQ: RXST) reported significant financial growth for Q4 2021, achieving $8.4 million in revenue, a 71% increase year-over-year. The fiscal year 2021 revenue totaled $22.6 million, up 54% from 2020. The company sold 45 Light Delivery Devices and 2,959 Light Adjustable Lenses in Q4 alone. Despite this growth, operating expenses surged by 81% to $17.5 million, resulting in a net loss of $(15.7) million for Q4. Looking ahead, RxSight projects 2022 revenue between $40.0 million and $44.0 million.
RxSight, Inc. (NASDAQ: RXST) announced it will release its financial results for the fourth quarter and fiscal year 2021 on March 8, 2022, after market close. A conference call with management will follow at 1:30 p.m. PT to discuss the results. The company specializes in ophthalmic medical devices aimed at enhancing post-cataract surgery vision through its innovative Light Adjustable Lens (LAL) system. This technology includes unique features like ActivShield™ for UV protection.
RxSight, Inc., an ophthalmic medical device company based in Aliso Viejo, California, has announced participation in the SVB Leerink Global Healthcare Conference. Management will join a fireside chat on February 17, 2022, at 12:40 PM PT / 3:40 PM ET. Interested audiences can access the live or archived webcast via the company's investor section. RxSight is recognized for its innovative Light Adjustable Lens system, which allows customization of visual acuity post-cataract surgery, now enhanced with ActivShield technology for UV protection.